Scott Plotkin

Scott Plotkin has a diverse work experience in the medical field. Scott started in 2003 as a Neuro-oncologist at Massachusetts General Hospital and went on to serve as the Director for the Massachusetts General Hospital Family Center for Neurofibromatosis. In 2005, they became the Executive Director at the Stephen E. and Catherine Pappas Center for Neuro-Oncology. Additionally, they held the position of Director for the Massachusetts General - Dana Farber - Brigham & Women's Neuro-Oncology Fellowship from 2006 to 2021. In 2019, they became the Interim Executive Director at Massachusetts General Hospital. Alongside these roles, they joined Harvard Medical School in 2011 as an Associate Professor of Neurology and later became the Armenise Family Harvard Professor of Neurology. In 2013, they also co-founded NFlection Therapeutics.

Scott Plotkin's education history can be summarized as follows:

Scott Plotkin attended Harvard University from 1987 to 1991 and obtained a Bachelor of Arts (BA) degree in Chemistry. Scott then went on to pursue further education at Tulane University, where they attended the School of Liberal Arts from 1992 to 1998. During this time, they earned a Doctor of Philosophy (PhD) degree in Neuroscience.

In addition to their PhD, Plotkin also attended Tulane University School of Medicine from 1992 to 1998, where they obtained a Doctor of Medicine (MD) degree.

Later, in 2003 to 2004, they attended Harvard T.H. Chan School of Public Health, where they earned a Certificate in Clinical Effectiveness.

Apart from their formal education, Scott Plotkin also obtained a certification from the CITI Program in January 2023. The certification is titled "Group 1: Biomedical Investigators and Key Personnel HSP and GCP (US FDA focus) Combined."